Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -18.38% is 493% below its 5-year average of -3.10%, near the low end of its 5-year range (-18.38%–23.69%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.54% below its 12-month average of -16.62%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -18.38%.
RETURN ON EQUITY (ROE)
-18.38%
RETURN ON EQUITY (ROE) AVG TTM
-16.62%
RETURN ON EQUITY (ROE) AVG 3Y
-15.14%
RETURN ON EQUITY (ROE) AVG 5Y
-3.10%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-10.54%
CURRENT VS 3Y AVG
-21.37%
CURRENT VS 5Y AVG
-492.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+56.26%
vs the sector median at left
AbCellera Biologics Inc.
Market Cap
$4.01B
Return on Equity (ROE)
-18.38%
TTM Avg
-16.62%
3Y Avg
-15.14%
5Y Avg
-3.10%
Market Cap
$4.03B
Return on Equity (ROE)
-32.14%
TTM Avg
-46.09%
3Y Avg
-42.05%
5Y Avg
-35.94%
Market Cap
$3.95B
Return on Equity (ROE)
1.40%
TTM Avg
-2.98%
3Y Avg
-2.73%
5Y Avg
0.21%
Market Cap
$4.11B
Return on Equity (ROE)
14.23%
TTM Avg
-7.71%
3Y Avg
-5.30%
5Y Avg
-10.52%
Market Cap
$3.76B
Return on Equity (ROE)
-73.75%
TTM Avg
-63.05%
3Y Avg
-54.60%
5Y Avg
-25.68%
Market Cap
$4.25B
Return on Equity (ROE)
-44.02%
TTM Avg
-30.64%
3Y Avg
-28.05%
5Y Avg
-12.80%
Market Cap
$4.33B
Return on Equity (ROE)
-44.68%
TTM Avg
-52.94%
3Y Avg
-55.51%
5Y Avg
-46.01%
Market Cap
$4.39B
Return on Equity (ROE)
-42.32%
TTM Avg
-13.82%
3Y Avg
-5.11%
5Y Avg
-5.11%
Market Cap
$3.57B
Return on Equity (ROE)
-12.08%
TTM Avg
-47.33%
3Y Avg
-44.55%
5Y Avg
-54.96%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.01B | -18.38% | -16.62% | -15.14% | -3.10% |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.03B | -32.14% | -46.09% | -42.05% | -35.94% |
| ICU Medical, Inc. (ICUI)vs › | $3.95B | 1.40% | -2.98% | -2.73% | 0.21% |
| LivaNova PLC (LIVN)vs › | $4.11B | 14.23% | -7.71% | -5.30% | -10.52% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.76B | -73.75% | -63.05% | -54.60% | -25.68% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.25B | -44.02% | -30.64% | -28.05% | -12.80% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.33B | -44.68% | -52.94% | -55.51% | -46.01% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.39B | -42.32% | -13.82% | -5.11% | -5.11% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -12.08% | -47.33% | -44.55% | -54.96% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.46B | N/A | -107.43% | -58.28% | -52.10% |
ROE
-18.4%
ROA
-12.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -18.38% |
| 2026-03-31 | -15.35% |
| 2025-12-31 | -15.14% |
| 2025-09-30 | -17.81% |
| 2025-06-30 | -16.45% |
| 2025-03-31 | -16.41% |
| 2024-12-31 | -15.42% |
| 2024-09-30 | -16.31% |
| 2024-06-30 | -13.80% |
| 2024-03-31 | -13.00% |
| 2023-12-31 | -12.70% |
| 2023-09-30 | -10.92% |
| 2023-06-30 | -6.19% |
| 2023-03-31 | -4.15% |
| 2022-12-31 | 12.85% |
| 2022-09-30 | 19.87% |
| 2022-06-30 | 16.52% |
| 2022-03-31 | 16.96% |
| 2021-12-31 | 14.96% |
| 2021-09-30 | 22.08% |
| 2021-06-30 | 23.69% |
| 2021-03-31 | 24.89% |
| 2020-12-31 | 14.32% |
| 2020-09-30 | 0.31% |
| 2020-06-30 | 3.31% |
| 2020-03-31 | -39.02% |
| 2019-12-31 | -21.56% |
